JIL SWANSON: Open Payments
NPI 1386792422 · WASHINGTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$20,807 in 206 payments from 21 companies in 2025. Trend: 2023 $3,422 · 2024 $13,020 · 2025 $20,807
Speaker / faculty: $15,750Food & beverage: $3,932Travel & lodging: $1,124
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 45 | $17,945 |
| Amgen Inc. | 11 | $390 |
| GENZYME CORPORATION | 14 | $315 |
| ABBVIE INC. | 37 | $297 |
| Novartis Pharmaceuticals Corporation | 9 | $275 |
| Lilly USA, LLC | 8 | $232 |
| UCB, Inc. | 17 | $230 |
| Galderma Laboratories, L.P. | 18 | $208 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 7 | $156 |
| MAYNE PHARMA COMMERCIAL LLC | 7 | $138 |
Products named: TREMFYA, OTEZLA, DUPIXENT, SKYRIZI, Bimzelx, EBGLYSS, NEMLUVIO, OPZELURA.
Industry payments across PA — which companies pay providers there.
